CA2307547C - Formulations chronotherapeutiques du diltiazem et administration de celles-ci - Google Patents

Formulations chronotherapeutiques du diltiazem et administration de celles-ci Download PDF

Info

Publication number: CA2307547C
Authority: CA; Canada
Prior art keywords: diltiazem; composition; hours; core; pharmaceutically acceptable
Prior art date: 1999-12-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002307547A

Other languages

English (en)

Other versions

CA2307547A1 (fr

Inventor

Kenneth Stephen Albert

Paul Jose Maes

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Valeant International Bermuda

Original Assignee

Biovail Laboratories International SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-10

Filing date

2000-05-04

Publication date

2007-08-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25681399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2307547(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-12-10 Priority claimed from CA002292247A external-priority patent/CA2292247A1/fr

2000-05-04 Application filed by Biovail Laboratories International SRL filed Critical Biovail Laboratories International SRL

2000-05-04 Priority to CA002307547A priority Critical patent/CA2307547C/fr

2000-05-04 Priority to CA002566590A priority patent/CA2566590C/fr

2000-05-08 Priority to US09/567,451 priority patent/US7108866B1/en

2000-05-23 Priority to DE60042168T priority patent/DE60042168D1/de

2000-05-23 Priority to AT00930909T priority patent/ATE430561T1/de

2000-05-23 Priority to JP2001543089A priority patent/JP2003516347A/ja

2000-05-23 Priority to AU49037/00A priority patent/AU4903700A/en

2000-05-23 Priority to PCT/CA2000/000593 priority patent/WO2001041744A1/fr

2000-05-23 Priority to EP00930909A priority patent/EP1235562B1/fr

2000-05-23 Priority to ES00930909T priority patent/ES2325826T3/es

2001-06-10 Publication of CA2307547A1 publication Critical patent/CA2307547A1/fr

2007-08-14 Publication of CA2307547C publication Critical patent/CA2307547C/fr

2007-08-14 Application granted granted Critical

2020-05-04 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229960004166 diltiazem Drugs 0.000 title claims abstract description 236
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 title claims abstract description 224
239000000203 mixture Substances 0.000 title claims description 160
238000009472 formulation Methods 0.000 title description 40
238000002360 preparation method Methods 0.000 claims abstract description 58
150000003839 salts Chemical class 0.000 claims abstract description 40
235000013305 food Nutrition 0.000 claims abstract description 34
210000004369 blood Anatomy 0.000 claims abstract description 19
239000008280 blood Substances 0.000 claims abstract description 19
238000013270 controlled release Methods 0.000 claims abstract description 16
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
239000002775 capsule Substances 0.000 claims description 41
239000011324 bead Substances 0.000 claims description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
239000011248 coating agent Substances 0.000 claims description 39
238000000576 coating method Methods 0.000 claims description 39
239000012528 membrane Substances 0.000 claims description 39
238000000034 method Methods 0.000 claims description 33
239000004531 microgranule Substances 0.000 claims description 30
238000004090 dissolution Methods 0.000 claims description 29
239000000080 wetting agent Substances 0.000 claims description 27
239000012530 fluid Substances 0.000 claims description 26
238000011282 treatment Methods 0.000 claims description 23
HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 claims description 22
239000002609 medium Substances 0.000 claims description 22
239000012982 microporous membrane Substances 0.000 claims description 19
230000007935 neutral effect Effects 0.000 claims description 19
230000002496 gastric effect Effects 0.000 claims description 18
238000000338 in vitro Methods 0.000 claims description 17
229920001577 copolymer Polymers 0.000 claims description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 15
229940068196 placebo Drugs 0.000 claims description 15
239000000902 placebo Substances 0.000 claims description 15
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 14
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
229920003163 Eudragit® NE 30 D Polymers 0.000 claims description 12
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
206010020772 Hypertension Diseases 0.000 claims description 11
239000012736 aqueous medium Substances 0.000 claims description 11
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 10
230000036571 hydration Effects 0.000 claims description 10
238000006703 hydration reaction Methods 0.000 claims description 10
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
239000000314 lubricant Substances 0.000 claims description 10
229920000642 polymer Polymers 0.000 claims description 10
206010002383 Angina Pectoris Diseases 0.000 claims description 9
239000000454 talc Substances 0.000 claims description 9
229910052623 talc Inorganic materials 0.000 claims description 9
SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
229920000053 polysorbate 80 Polymers 0.000 claims description 8
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 7
239000002671 adjuvant Substances 0.000 claims description 7
239000000470 constituent Substances 0.000 claims description 7
238000002156 mixing Methods 0.000 claims description 7
FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 claims description 6
-1 C20 fatty acid esters Chemical class 0.000 claims description 6
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
229960005316 diltiazem hydrochloride Drugs 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
235000019359 magnesium stearate Nutrition 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
230000007246 mechanism Effects 0.000 claims description 6
229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
239000008108 microcrystalline cellulose Substances 0.000 claims description 6
239000004014 plasticizer Substances 0.000 claims description 6
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
229940068968 polysorbate 80 Drugs 0.000 claims description 6
229920003081 Povidone K 30 Polymers 0.000 claims description 5
239000000839 emulsion Substances 0.000 claims description 5
210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
150000007524 organic acids Chemical group 0.000 claims description 5
239000008213 purified water Substances 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
229920003152 Eudragit® RS polymer Polymers 0.000 claims description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
230000008901 benefit Effects 0.000 claims description 4
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims description 4
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims description 4
229920000058 polyacrylate Polymers 0.000 claims description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
239000011148 porous material Substances 0.000 claims description 4
229940069328 povidone Drugs 0.000 claims description 4
229940083037 simethicone Drugs 0.000 claims description 4
229920003151 Eudragit® RL polymer Polymers 0.000 claims description 3
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
238000009792 diffusion process Methods 0.000 claims description 3
150000004677 hydrates Chemical class 0.000 claims description 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
235000000346 sugar Nutrition 0.000 claims description 3
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
239000001361 adipic acid Substances 0.000 claims description 2
235000011037 adipic acid Nutrition 0.000 claims description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
235000015165 citric acid Nutrition 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
239000001530 fumaric acid Substances 0.000 claims description 2
235000011087 fumaric acid Nutrition 0.000 claims description 2
210000000936 intestine Anatomy 0.000 claims description 2
239000000787 lecithin Substances 0.000 claims description 2
235000010445 lecithin Nutrition 0.000 claims description 2
239000001630 malic acid Substances 0.000 claims description 2
235000011090 malic acid Nutrition 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
229910052751 metal Inorganic materials 0.000 claims description 2
239000002184 metal Substances 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
235000010356 sorbitol Nutrition 0.000 claims description 2
150000008163 sugars Chemical class 0.000 claims description 2
239000011975 tartaric acid Substances 0.000 claims description 2
235000002906 tartaric acid Nutrition 0.000 claims description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
235000010447 xylitol Nutrition 0.000 claims description 2
125000000969 xylosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 claims description 2
239000006186 oral dosage form Substances 0.000 claims 9
229920001477 hydrophilic polymer Polymers 0.000 claims 6
239000002202 Polyethylene glycol Substances 0.000 claims 2
229920006243 acrylic copolymer Polymers 0.000 claims 2
125000000524 functional group Chemical group 0.000 claims 2
150000002334 glycols Chemical class 0.000 claims 2
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 2
229920001223 polyethylene glycol Polymers 0.000 claims 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 1
238000013268 sustained release Methods 0.000 abstract description 13
239000012730 sustained-release form Substances 0.000 abstract description 13
239000002552 dosage form Substances 0.000 abstract description 11
230000002035 prolonged effect Effects 0.000 abstract description 3
230000002459 sustained effect Effects 0.000 abstract description 3
239000003814 drug Substances 0.000 description 29
239000003826 tablet Substances 0.000 description 28
229940079593 drug Drugs 0.000 description 26
239000008188 pellet Substances 0.000 description 13
238000012360 testing method Methods 0.000 description 12
230000036772 blood pressure Effects 0.000 description 11
238000009826 distribution Methods 0.000 description 11
230000000694 effects Effects 0.000 description 11
238000011551 log transformation method Methods 0.000 description 11
210000002381 plasma Anatomy 0.000 description 11
239000001993 wax Substances 0.000 description 11
238000000540 analysis of variance Methods 0.000 description 10
238000010410 dusting Methods 0.000 description 7
239000000843 powder Substances 0.000 description 7
239000000463 material Substances 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
229940079832 sodium starch glycolate Drugs 0.000 description 6
229920003109 sodium starch glycolate Polymers 0.000 description 6
239000008109 sodium starch glycolate Substances 0.000 description 6
238000007619 statistical method Methods 0.000 description 6
238000013179 statistical model Methods 0.000 description 6
239000004408 titanium dioxide Substances 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
230000036765 blood level Effects 0.000 description 5
238000013461 design Methods 0.000 description 5
239000012729 immediate-release (IR) formulation Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
230000002060 circadian Effects 0.000 description 4
239000003168 generic drug Substances 0.000 description 4
239000008172 hydrogenated vegetable oil Substances 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
229940035248 tiazac Drugs 0.000 description 4
230000009466 transformation Effects 0.000 description 4
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
238000001035 drying Methods 0.000 description 3
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 3
238000013265 extended release Methods 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
238000005507 spraying Methods 0.000 description 3
238000012109 statistical procedure Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229960001722 verapamil Drugs 0.000 description 3
229940127291 Calcium channel antagonist Drugs 0.000 description 2
229920003134 Eudragit® polymer Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002518 antifoaming agent Substances 0.000 description 2
235000021152 breakfast Nutrition 0.000 description 2
239000000480 calcium channel blocker Substances 0.000 description 2
230000007211 cardiovascular event Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
229940044369 dilacor Drugs 0.000 description 2
238000009506 drug dissolution testing Methods 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000004200 microcrystalline wax Substances 0.000 description 2
235000019808 microcrystalline wax Nutrition 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
239000000049 pigment Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000630 rising effect Effects 0.000 description 2
230000035939 shock Effects 0.000 description 2
230000007480 spreading Effects 0.000 description 2
238000003892 spreading Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
241001463143 Auca Species 0.000 description 1
GMRSQCVLGPQPFT-UHFFFAOYSA-N C(=O)=O.[O-2].[O-2].[Ti+4].C(CO)(=O)O Chemical compound C(=O)=O.[O-2].[O-2].[Ti+4].C(CO)(=O)O GMRSQCVLGPQPFT-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010049418 Sudden Cardiac Death Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229920000704 biodegradable plastic Polymers 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Natural products O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000013501 data transformation Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000011978 dissolution method Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
238000001151 non-parametric statistical test Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
229950002273 simeticone Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000005919 time-dependent effect Effects 0.000 description 1
229960005196 titanium dioxide Drugs 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002307547A 1999-12-10 2000-05-04 Formulations chronotherapeutiques du diltiazem et administration de celles-ci Expired - Lifetime CA2307547C (fr)

Priority Applications (10)

Application Number	Priority Date	Filing Date	Title
CA002307547A CA2307547C (fr)	1999-12-10	2000-05-04	Formulations chronotherapeutiques du diltiazem et administration de celles-ci
CA002566590A CA2566590C (fr)	1999-12-10	2000-05-04	Formulations chronotherapeutiques du diltiazem et administration de celles-ci
US09/567,451 US7108866B1 (en)	1999-12-10	2000-05-08	Chronotherapeutic diltiazem formulations and the administration thereof
ES00930909T ES2325826T3 (es)	1999-12-10	2000-05-23	Formulaciones de diltiazem cronoterapeuticas y su administracion.
JP2001543089A JP2003516347A (ja)	1999-12-10	2000-05-23	時間療法用ジルチアゼム製剤およびその投与法
AT00930909T ATE430561T1 (de)	1999-12-10	2000-05-23	Chronotherapeutische diltiazem formulierungen und deren verabreichung
DE60042168T DE60042168D1 (de)	1999-12-10	2000-05-23	Chronotherapeutische diltiazem formulierungen und deren verabreichung
AU49037/00A AU4903700A (en)	1999-12-10	2000-05-23	Chronotherapeutic diltiazem formulations and the administration thereof
PCT/CA2000/000593 WO2001041744A1 (fr)	1999-12-10	2000-05-23	Formulations a base de diltiazem chronotherapeutiques et leur administration
EP00930909A EP1235562B1 (fr)	1999-12-10	2000-05-23	Formulations a base de diltiazem chronotherapeutiques et leur administration

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CA2,292,247		1999-12-10
CA002292247A CA2292247A1 (fr)	1999-12-10	1999-12-10	Formulations chronotherapeutiques du diltiazem et administration de celles-ci
CA002307547A CA2307547C (fr)	1999-12-10	2000-05-04	Formulations chronotherapeutiques du diltiazem et administration de celles-ci

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002566590A Division CA2566590C (fr)	1999-12-10	2000-05-04	Formulations chronotherapeutiques du diltiazem et administration de celles-ci

Publications (2)

Publication Number	Publication Date
CA2307547A1 CA2307547A1 (fr)	2001-06-10
CA2307547C true CA2307547C (fr)	2007-08-14

Family

ID=25681399

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA002566590A Expired - Lifetime CA2566590C (fr)	1999-12-10	2000-05-04	Formulations chronotherapeutiques du diltiazem et administration de celles-ci
CA002307547A Expired - Lifetime CA2307547C (fr)	1999-12-10	2000-05-04	Formulations chronotherapeutiques du diltiazem et administration de celles-ci

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CA002566590A Expired - Lifetime CA2566590C (fr)	1999-12-10	2000-05-04	Formulations chronotherapeutiques du diltiazem et administration de celles-ci

Country Status (1)

Country	Link
CA (2)	CA2566590C (fr)

2000
- 2000-05-04 CA CA002566590A patent/CA2566590C/fr not_active Expired - Lifetime
- 2000-05-04 CA CA002307547A patent/CA2307547C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2566590A1 (fr)	2001-06-10
CA2566590C (fr)	2008-04-15
CA2307547A1 (fr)	2001-06-10

Legal Events

Date	Code	Title	Description
2000-05-04	EEER	Examination request
2020-07-06	MKEX	Expiry	Effective date: 20200504

Publication	Publication Date	Title
US20090118256A1 (en)	2009-05-07	Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en)	2006-09-19	Chronotherapeutic diltiazem formulations and the administration thereof
US9173857B2 (en)	2015-11-03	Controlled dose drug delivery system
CA2462637C (fr)	2010-12-07	Formes posologiques a particules multiples et a liberation echelonnee de propanolol
KR101207618B1 (ko)	2012-12-04	심혈관계 질환 치료용 약제학적 제제
JP4072597B2 (ja)	2008-04-09	持続性製剤
JP5687185B2 (ja)	2015-03-18	多粒子系を含む二段階の放出プロフィールを有する固形経口剤
CA2651890C (fr)	2015-01-27	Systeme d'administration de medicament par doses controlees
JP2003508430A (ja)	2003-03-04	トラマドールサッカリナートを含有する徐放性投薬形
AU2002330211A1 (en)	2003-06-26	Timed, sustained release multi-particulate dosage forms of propranolol
JP2008520633A (ja)	2008-06-19	少なくとも１つの有効成分の放出を改変するためのマルチマイクロカプセル形態の経口医薬
CN109069480A (zh)	2018-12-21	用于治疗与癫痫相关的病症的方法和组合物
CA2782556A1 (fr)	2011-06-09	Compositions d'amantadine et procedes d'utilisation associes
HUP0201687A2 (en)	2002-09-28	Oral administration form for administering a fixed tramadol and diclofenac combination
JP2003528905A (ja)	2003-09-30	スタブジン含有持続放出性ビーズ剤
CA2307547C (fr)	2007-08-14	Formulations chronotherapeutiques du diltiazem et administration de celles-ci
US20060153914A1 (en)	2006-07-13	Chronotherapeutic diltiazem formulations and the administration thereof
UA81121C2 (en)	2007-12-10	Microcapsules for the delayed, controlled release of perindopril, use thereof for the preparation of pharmaceutical composition and pharmaceutical composition containing microcapsules
WO2010036975A2 (fr)	2010-04-01	Formulations de dipyridamole et d'acide acétylsalicylique et leur procédé de préparation
CA2292247A1 (fr)	2001-06-10	Formulations chronotherapeutiques du diltiazem et administration de celles-ci
JPH05139964A (ja)	1993-06-08	塩酸メキシレチン腸溶性製剤